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Stem cells in bone regeneration 
Abstract
Bone defects, including normal fracture healing as well as healing prob-
lems represent a global health problem. The need for better treatment of bone 
defects is one of the central issues of tissue engineering and regenerative 
medicine. Regenerative orthopedics has several approaches – activation of 
endogenous stem cells, stem cell therapy and tissue engineering. Development 
of new treatments is mainly focused on the tissue engineering strategies that 
include stem cells, bioactive signals and appropriate scaffold support. 
The aim of this review is to describe a variety of stem cells that have an 
ability to become bone cells and therefore are of central importance for bone 
tissue engineering. Several cell types have been proposed as starting material 
- embryonic stem cells, induced pluripotent stem cells and adult stem cells. 
Due to ethical and safety issues, embryonic and induced pluripotent stem 
cells may be more suitable for studying human development and tissue for-
mation under diverse experimental conditions, and represent an excellent 
base for understanding human diseases and development of innovative 
therapeutic solutions. Among adult stem cells, mesenchymal stem cells are 
the most suitable for bone tissue engineering. They can be isolated from 
variety of mesenchymal tissues and can differentiate into osteoblasts when 
given appropriate mechanical support and osteoinductive signal. 
The near future of bone healing and regeneration is closely related to 
advances in tissue engineering. The optimization of protocols of bone graft 
production using autologous mesenchymal stem cells loaded on appropriate 
scaffolds, exposed to osteogenic inducers and mechanical force in bioreactor, 
should be able to solve the current limitations in managing bone injuries.
INTRODUCTION
Bone is a specialized form of connective tissue supporting the whole organism in higher vertebrates. Besides the liver, bone is the only 
tissue that can spontaneously heal and restore its function without leav-
ing a scar. It is highly vascularized and subject to constant remodeling. 
Thus bone has the ability to regenerate after injury, however this is only 
the case if the injury is below the critical size. Because of prolonged 
lifetime, bone diseases such as infections, fractures and osteoarthritis, 
osteoporosis and spine diseases become a major socio-economic prob-
lem. Bone defects are one of the leading causes of morbidity and dis-
ability in elderly patients, leading to decreases in overall health and 
quality of life and there is an urgent need for more effective means of 
bone reconstruction (1). Regenerative orthopedics has several approach-
es to bone reconstruction – activation of endogenous stem cells, stem 
cell therapy and tissue engineering. Tissue engineering is the ‘final’ op-
tion in managing bone loss (2). The area of bone tissue engineering aims 
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ogy and engineering to develop functional replacements 
for damaged tissue. Approximately 600,000 bone graft 
procedures are performed each year in the United States, 
and about 2.2 million of such procedures are performed 
annually worldwide (3, 4). It is based on three compo-
nents and includes the successful interaction of these 
components: (i) cells that are responsible for the produc-
tion of tissue, (ii) a carrier that holds cells together and 
creates a physical, three-dimensional shape of the tissue, 
(iii) growth factors that direct the cells to the desired bone 
phenotype tissue (5).  It has been proven that osteoblasts, 
human mesenchymal stem cells (hMSCs), human embry-
onic stem cell-derived MSCs (hESC-MSCs) and human 
induced pluripotent stem cell-derived MSCs (hiPSC-
MSCs) all successfully produce bone grafts when attached 
to proper mechanical support (6) with the addition of 
osteogenic supplements (Figure 1).
The aim of this review is to describe the current state 
of the art in our understanding of different types of stem 
cells that can participate in bone regeneration and seeks 
to describe the challenges that scientists face in finding a 
successful protocol for the bone healing.
CELLS
Bone is a dynamic biological tissue consisting of meta-
bolically active cells. The cell component of bone consists 
of the precursor cells (progenitors), osteoblasts, osteoclasts, 
osteocytes and bone marrow hematopoietic elements. Os-
teoblasts are metabolically active mature bone-forming 
cells (7). They secret osteoid, non-mineralized organic cor-
puscle which in turn undergoes mineralization process. 
Osteocytes are mature osteoblasts trapped within the bone 
matrix. Every osteocyte extends network of cytoplasmic 
tubules to the blood vessels and other cells. These cells are 
involved in the control of extracellular calcium. Osteo-
clasts are large multinucleated cells that degrade bone (8). 
Beside cells, bone is also composed of organic and inor-
ganic elements. Approximately 20% of the weight of bone 
is water until the weight of dry inorganic bone makes cal-
cium phosphate (65-70%) and the organic matrix of fi-
brous proteins and collagen (30-35%)(8).
Bone formation models in vitro are based on the fact 
that cell differentiation and function can be modeled ac-
cording to factors that are important for embryonic de-
velopment. The formation of the skeletal elements starts 
with cell condensation process where scattered mesenchy-
mal stem cells migrate, proliferate and are connected by 
adhesion molecules. Stem cells represent the building 
blocks of our bodies, functioning as the natural units of 
embryonic generation during development and adult re-
generation following tissue damage (9). Owing to their 
unique regenerative capacity, stem cells have generated 
great enthusiasm worldwide and represent an invaluable 
tool with unprecedented potential for biomedical research 
and therapeutic applications (10). 
Stem cells are undifferentiated cells that can, under cer-
tain influence differentiate into specialized cells and tis-
sues. During development, potency of stem cells decreases 
from totipotent stem cells (morula stage), capable of dif-
ferentiating into all embryonic and extra embryonic tis-
sues, to pluripotent stem cells (blastocyst stage), forming 
all embryonic tissues and to multi- or unipotent adult stem 
cells, forming tissues within their germ layer. Here, we 
Figure 1. Stem cells with bone regeneration potential. 
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discuss three types of stem cells: embryonic stem cells iso-
lated from the inner cell mass of blastocysts, induced plu-
ripotent stem cells generated from somatic cells by intro-
duction of key transcription factors (10) and adult stem 
cells found in various adult tissues. Adult stem cells, also 
called somatic stem cells, in adult organism act as repair 
system for the body, replenishing adult tissues, prompt tis-
sue homeostasis throughout life and ensure tissue regen-
eration following damage and they have great potential in 
regenerative medicine (10). Mesenchymal stem cells re-
plenish connective tissues including bone. Therefore, they 
are the first choice among adult stem cells for regeneration 
of bone tissue. Adult stem cells have ability to differentiate 
in in vitro conditions and following differentiation can be 
implanted back into the patient (11). They can also be pas-
saged in vitro until they achieve the sufficient number of 
cells and then implanted in the patient (12). Osteogenic 
differentiation in vitro is induced by ascorbic acid, b-glyc-
erophosphate and dexamethasone (13). This approach 
avoids stem cells differentiation into unwanted forms of 
tissue and also prevents the risk of malignant transforma-
tion. Regardless these advantages they are still difficult to 
passage in vitro and they often lose their phenotype. 
1. Embryonic stem cells (ESCs)
ESCs were first isolated from mouse embryo by Nobel 
Prize Martin Evans and his team (14). ESCs are considered 
fully pluripotent, which means that they can differentiate 
into all three germ layers. After while embryonic stem cells 
were also isolated from human embryo in the late 1990s 
(15).  Human ESCs (hESCs) grow in compact colonies on 
feeder layers of murine embryonic fibroblasts or human 
cells, which produce the extracellular matrix for cell attach-
ment and condition the culture medium with paracrine 
factors.  hESCs culture media were supplemented with 
fetal bovine serum of selected lots, serum replacement and 
with growth factors which activate the intracellular signal-
ing networks maintaining pluripotency (10).  Although 
they present many advantages for regenerative medicine 
and tissue engineering, many ethical issues limit their use 
and many countries prohibit ESCs isolation from human 
embryo. Because these particular cells have created an 
ethical debate, other researchers have begun to use embry-
onic or fetal cells derived from voluntary interruption of 
pregnancy between 5 and 8 weeks (16). Darja Marlot and 
her team demonstrated that human ESC-derived mesen-
chymal progenitors can be induced to form compact, ho-
mogenous and phenotypically stable bone-like tissue by 
cultivation on 3D osteoconductive scaffolds in bioreactors 
with interstitial flow of culture medium. They developed a 
stepwise protocol to engineer bone-like constructs from 
hESCs. The engineered bone tissue was stable for 8 weeks 
in vivo and exhibited signs of continued bone development, 
indicating a potential for bone defect regeneration (17). 
Vunjak-Novakovic G and her team focused on the effects 
of the matrix architecture and mineral content in scaffolds 
on bone formation by hESC. Mesenchymal progenitors 
derived from hESCs were cultured for 5 weeks in decel-
lularized bone scaffolds with three different mineral densi-
ties. They conclude that minerals were beneficial for the 
higher expression of bone markers in cultured cells and 
more robust accumulation of the new bone matrix (17). 
Besides ethical controversy, there are more problems with 
human embryonic cells as they can easily form a tumor 
tissue and they are not immunologically compatible. 
2. Induced pluripotent stem cells 
(iPSCs)
Studying the transcription factors involved in human 
embryonic development, scientist found out that when 
fibroblasts are exposed to defined cocktail of transcription 
factors (Oct3 /4, Sox2, KLF4 andc-Myc), they become 
pluripotent and have the ability to differentiate into other 
tissues. Reprogramming of already differentiated cells 
bypass the ethical problems that have occurred with hu-
man embryonic stem cells. Discovery of these pluripotent 
stem cells contribute greatly to the development of regen-
erative medicine and opened many new areas in the stem 
cell biology and their use in disease treating (18–20). 
Moreover, induced pluripotent stem cells (iPSCs), which 
are ESC-like pluripotent cells have brought new hope to 
tissue engineering and regenerative medicine because of 
their full pluripotent differentiation potential and excel-
lent performance in bone regeneration (21). Earlier last 
year a group of scientists led by the M. Tang examined 
what will happen with iPS cells when they were cultured 
in a calcium phosphate scaffold (CPC) (22). iPSCs were 
cultured to form embryoid bodies (EBs) and MSCs mi-
grated out of EBs. Their aim was to produce iPS cell-de-
rived mesenchymal stem cells (iPS-MSCs), seed them on 
calcium phosphate scaffold and observe cell attachment 
and proliferation. iPSC-MSCs showed good viability and 
osteogenic differentiation on CPC scaffold for the first 
time, but the process was quite complex. To generate os-
teoprogenitor cells from iPSCs, the most widely used 
protocol relies on an intermediate embryoid body (EB) 
formation, but recently Dogaki Y. with his team hypoth-
esized that an osteoprogenitor cell population could be 
efficiently generated from iPSCs without the EB forma-
tion step and they tried ‘direct-plating’ method  (23). 
They isolated a murine iPSCs colony and grew it into a 
medium for the MSC, after 14 days of osteogenic induc-
tion, cells proved to have a high osteogenic differentiation 
capacity, significant increase in alkaline phosphatase ac-
tivity, expression of osteogenic genes and mineralization. 
When compared with ESCs, iPSCs bypass the problems 
with ethical controversy and immunogenicity, but there 
is still the possibility of tumor tissue formation. 
3. Adult stem cells (ASCs)
Adult stem cells are found in the post-natal body with-
in their specific niches and they have limited differentia-
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tion capacity. ASCs are applied extensively in regenerative 
medicine because they can be harvested from the indi-
vidual, cultivated in vitro, exhibited to appropriate factors 
depending on the tissue we want to get and then im-
planted back into the patient. Since the cells are autolo-
gous, the immune response is avoided and all ethical 
questions are circumvented. Adult stem cells also repre-
sent a less risk of malignant transformation. In a living 
organism, adult stem cells are capable to divide when 
needed and can give rise to mature cell types that have 
characteristic shapes and specialized structures and func-
tions of a particular tissue. Hematopoietic stem cells give 
rise to all the types of blood cells (24). Neural stem cells in 
the brain give rise to its three major cell types: nerve cells 
(neurons) and two categories of non-neuronal cells—as-
trocytes and oligodendrocytes (25). Mesenchymal stem cells 
have been reported to be present in many tissues. Those 
from bone marrow give rise to a variety of cell types: bone 
cells (osteoblasts and osteocytes), cartilage cells (chondro-
cytes), fat cells (adipocytes) and stromal cells that support 
blood formation (26–28).
3.1. Mesenchymal stem cells (MSCs)
Among stem cells, mesenchymal stem cells (MSCs) 
seem to be more suitable for bone engineering compared 
to ESCs and iPSCs due to several characteristics that they 
possess. Mesenchymal stem cells are multipotent cell 
population present in the bone marrow and other tissues, 
including adipose tissue. MSCs can differentiate into os-
teoblasts, chondrocytes, adipocytes and myocytes in vitro 
(29). They have proliferation and differentiation ability, 
making them a great candidates for tissue engineering 
and regenerative medicine (30). For regeneration of bone, 
MSCs were isolated from bone marrow and they can be 
used alone or in combination with the osteoinductive sig-
nal to facilitate bone healing. MSCs is often isolated based 
on their properties to attach on the plastic surface on 
which they are growing. The number of these cells in the 
bone marrow varies (from 0.001 to 0.1%) between differ-
ent patients and it is considered to decrease with increas-
ing age of the patient. However, cells can proliferate and 
achieve up to 50 population distribution  in vitro (31). 
Successful cultivation of MSCs in vitro requires an un-
derstanding of signaling pathways that lead the prolifera-
tion and differentiation of these cells. Many chemical, 
biological and mechanical factors determine which path 
cells will follow and whether they will stay multipotent 
or differentiate into a specific cell type (29). MSCs dif-
ferentiation to specific cell lines may be accomplished in 
vitro (32). Osteogenic differentiation in vitro is induced 
by ascorbic acid, b-glycerophosphate and dexamethasone 
(13). Ascorbic acid is essential for the development of os-
teoblasts, serves as a cofactor in the synthesis of collagen 
and stimulates the production of extracellular matrix, 
proliferation and differentiation of cells. b-glycerophos-
phate serve as a source of phosphate for the formation of 
calcium phosphate in vitro. It is also responsible for the 
formation of three-dimensional bone nodules between 
cells as proof of realized osteoblast phenotype. Dexa-
methasone (DEX) is composed by a synthetic glucocor-
ticoid, which regulates the expression of osteoblastic 
genes, in vitro enhances differentiation, alkaline phospha-
tase activity and mineralization of bone (32). When the 
MSCs are cultured in osteogenic medium they differenti-
ate into osteoblasts that play the role in bone formation 
and formation of extracellular matrix and minerals. Os-
teogenic differentiation is divided into three phases (Fig-
ure 2). The first phase of proliferation lasts 4 days. After 
that in the period from 5 to 14 day the cells start to change 
and express alkaline phosphatase, type1collagen and they 
excrete extracellular matrix. The final phase lasts from 
14th until 28th day and results in high expression of os-
teocalcin, osteopontin and mineralization (13). The fate 
of MSCs is dependent on their microenvironment par-
ticularly the extracellular matrix that regulates the bal-
ance between self-renewal and differentiation through 
different cytokines, growth factors and mechanical stim-
uli (33). Mesenchymal stem cells have been used in bone 
regeneration for quite some time, but their disadvantages 
such as reduced proliferation rate or osteogenic potential 
decrease during aging greatly limit their application in 
tissue engineering and regenerative medicine.
Figure 2. Lineage-specific differentiation of mesenchymal stem cells (MSCs) through three stages of differentiation from 0-21 days.
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Sources of MSCs for bone regeneration 
Stem cell niche enable homeostasis and retains the 
ability of stem cells to self-renew (34). MSCs are located 
next to vessels walls, on the surface of the trabecular bone, 
in umbilical blood, within dental tissue and synovial 
fluid. But the most important source of stem cells for 
repair of the skeleton are derived from bone marrow, end-
osteum and perivascular cells. Team of scientists led by 
Ryu H. H. (35) isolated MSCs from fat and monitored 
their osteogenic potential  comparing them with MSCs 
from the bone marrow. There were no significant differ-
ences in functional recovery among the MSCs groups. 
Scientist also isolated the MSCs from other types of tis-
sues. Bugarski D with his team tried to compare the char-
acteristics of MSCs derived from two different human 
tissues: peripheral blood (PB-MSCs) and umbilical cord 
(UC-MSCs) (36). Cells were isolated according to the 
adherence to plastic after gradient-density separation or 
an explant culture method, respectively and compared 
regarding their morphology, clonogenic efficiency, prolif-
erating rates and differentiation potential. MSCs derived 
from both sources exhibit similar morphology, prolifera-
tion capacity and multipotency. Results demonstrated 
that both MSCs represent good alternative sources of 
adult MSCs that could be used in cell therapy applica-
tions. One year after that, Polianskaia G.G. with his team 
analyzed the characteristics of mesenchymal stem cell 
lines isolated from different tissues of 5-6-weeks human 
embryo: bone marrow (line FetMSC) and muscle of limb 
(line M-FetMSC) (37). They confirmed MSC status for 
FetMSC and M-FetMSC lines and number of interlinear 
differences related to growth characteristics and differen-
tiation potential were revealed. Suggesting the possible 
influence of different microenvironments in which the 
cells are in the body before their growth in vitro. For many 
years, bone marrow is still the most important source of 
stem cells. Although the sources of stem cells are wide-
spread and studies have shown that they do not differ 
much in osteogenic potential, the ideal stem cell source 
for bone regeneration should be easily accessible, non-
invasive and cell should be rapidly expandable by in vitro 
culture. The data collected so far have shown that adipose 
tissue is an abundant source of MSC and due to its wide 
body distribution makes it accessible by minimally inva-
sive methods. These MSC are also easy to isolate and ex-
pand in vitro (38).
Mesenchymal stem cells-based therapies
Mesenchymal stem cells have been used in the clinic 
for approximately 10 years. From animal models to clin-
ical trials, MSCs have afforded promise in the treatment 
of numerous diseases, mainly tissue injury and immune 
disorders (39). For example, in the 2010s Yoshikawa T. 
and his team analyzed the regenerative ability of autolo-
gous MSCs in degenerated intervertebral discs. Patients 
had lumbago, leg pain, and numbness. MSCs were from 
the patient marrow fluid and were cultured using the me-
dium containing autogenous serum and then were graft-
ed on collagen sponge. Two years after surgery, radio-
graph and computed tomography showed improvements 
in the vacuum phenomenon in both patients (40). Mes-
enchymal stem cell (MSC) transplantation shows exciting 
promise for the future regenerative approach to interver-
tebral disc disease. Many people worldwide suffer from 
bone defects due to trauma or disease. Usually small bone 
defects heal spontaneously but large defects cannot regen-
erate without intervention (41). When injury occurs 
MSCs are activated and they secrete signals that are tro-
phic and immunomodulatory telling us the true potential 
of MSC-based cell therapy. The stem cells trigger or acti-
vate the body’s own healing system. This MSCs immu-
nosuppressive properties have been explored in cell/organ 
transplant, tissue repair, autoimmune diseases and pre-
vention of graft versus host disease (GVHD) (42). For 
example, MSCs have been successfully applied to GvHD 
in patients receiving bone marrow transplantation and in 
patients diagnosed with severe steroid resistance (39). 
Taking into consideration the impact on the suppression 
of GVHD and inducing remission within the organism, 
MSC were investigated for the purpose of treating inflam-
matory bowel disease, type1diabetes and chronic obstruc-
tive pulmonary disease (43). Some studies in mice suggest 
that MSCs can promote formation of new blood vessels 
in a process called neovascularization. MSCs do not make 
new blood vessel cells themselves, but they stimulate the 
growth of the endothelial precursors – cells that will de-
velop to form the inner layer of blood vessels (44). Group 
of scientists led by Nicolas C. R cultured hMSCs from 
bone marrow with human umbilical vein endothelial cells 
(HUVECs) in differentiation medium in vitro. The co-
culture of cellular aggregates of hMSC (92%) and HU-
VEC (8%) supports the formation of a primitive three-
dimensional vascular network. This study demonstrated 
that the in vitro development of engineered vasculatures 
leads to a more functional, stable vasculature in vivo (45). 
The ability of MSCs to secrete such factors is recognized 
as an important component of their ability to promote 
tissue regeneration. It may be possible to allograft them 
for the purposes of bone regeneration and this would ob-
viate the need for treating each patient with his own cells, 
thus simplifying and streaming the entire process. 
Great success was achieved in the treatment of bone 
diseases with mesenchymal stem cells in animal models 
but a lot of gaps in our knowledge need to be filled in 
ordertobe able to use MSCs in clinical practice. It is still 
unknown mechanism of MSC-mediated bone regenera-
tion in vivo and because of that it is difficult to maintain 
a stable phenotype of MSCs in vitro (46).  To promote 
bone regeneration several treatment approaches have been 
used and the most common treatment is direct injection 
of MSCs. The MSCs can be better delivered to the site of 
injury bone if they are connected to three-dimensional 
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(3D) scaffold that mimics the mechanical and biological 
role of extracellular matrix. Therefore, the design of such 
scaffold is crucial for therapy with mesenchymal stem 
cells. Such scaffolds have the potential to provide the cor-
responding 3D environment for the growth and differen-
tiation of cells (13).
MSC-bone constructs
Bone constructs fabricated using scaffolds, cells and 
growth factors could be appropriate substitutes for bone 
transplantation (Figure 3). The general approach to bone 
tissue engineering is the first selection of cells and then 
the scaffold that will be seeded with cells. Three-dimen-
sional scaffolds made of biomaterials are developed as an 
interim basis for the growth of cells in an organized man-
ner. It is also well known that the three-dimensional or-
ganization of cells will affect cell development (33, 47). 
Preferably they need to be biocompatible, biodegradable 
and mimic in vivo structure of the bone tissue. The cells 
in the body are surrounded by or embedded in an extra-
cellular matrix, thus scaffold should have the properties 
that mimic the environment (30). These properties con-
tribute to the cell attachments, proliferation and differen-
tiation.
There are two types of scaffolds, natural and synthetic. 
Natural biomaterials alginate, chitosan, collagen, fibrin, 
hyaluronic acid and hydroxyapatite are extensively used 
for growing tissues because of the similarity with the ex-
tracellular matrix. However, the problems in the align-
ment properties and the source of these materials do not 
eliminate the problems of immune rejection of grafts. 
When synthesized, polymers can be determined with pre-
cise design of physical properties, but still we have the 
problem with biocompatibility.  In order to achieve the 
best possible integration into the host tissue researchers 
are using composite materials which are combination of 
natural and synthetic materials (47).
Group of scientists led by Prosecká E presented a new 
type of scaffold. They combined type 1 collagen and hy-
droxyapatite enriched with polycaprolactone nanofibers 
(Coll/HA/PCL) (48). They planted MSCs on scaffold in 
osteogenic media and thrombocyte-rich solution. Scaffold 
was implanted into the white rabbit and they watched 
bone regeneration in vivo. Results have shown that the 
installation of nanofibers in the scaffold and thrombo-
cytes in combination with MSC represent a novel treat-
ment for bone defects. This unique fusion between nano-
technology and biotechnology offers unprecedented 
possibilities in studying and modulating biological pro-
cesses on a molecular and atomic scale. Later in August a 
group of scientists led by the Anne-Laure Gamblin pre-
sented also their type of scaffold. They made calcium 
phosphate (CaP) ceramics scaffold and seed them with 
human mesenchymal stem cells (hMSC). Scaffold was 
implanted in paratibial muscle of nude mice. After 8 
weeks, at the site of implanted scaffold they noted a for-
mation of bone tissue, but the mechanism of osteoinduc-
tion by hMSC with CaP stay unclear (49, 50).
Controlled release of small molecules, growth factors 
and osteoinductive signals from the scaffold is very im-
portant for osteogenic differentiation, especially for ther-
apeutic applications. Bone morphogenetic proteins 
(BMPs) have a greatability to induce differentiation of 
osteoblasts and are often used as osteoinductive signals 
embedded in the scaffold for the differentiation of stem 
cells in vivo. BMPs are family members of transforming 
growth factor-beta (TGF-b). This is afamily of signaling 
proteins that regulate a large number of cellular activities, 
including differentiation, proliferation, migration, apop-
tosis and bone formation (51). Currently, the FDA ap-
proved technique is the implantation of the collagen car-
rier with BMP2 signal (52, 53). Collagen scaffold was 
soaked in recombinant BMP2. This technique, although 
clinically accepted, shows poorly controlled release of 
BMP resulting in high concentrations in the beginning, 
well above normal physiological conditions, that quickly 
decrease and wash out (54). Beside the bone regeneration, 
BMP2 is studied also in cartilage repair (55).
CONCLUSION
Bone defects that are due to trauma or pathological 
and physiological bone resorption represent a global 
health problem. The need for bone regeneration is one of 
the central issues in regenerative medicine. Cellular ther-
apy and tissue engineeringare becoming a useful addition 
to medical therapies for repairing and restoring function 
Figure 3. Bone graft after 21 days of cultivation of human mesen-
chymal stem cells on peptide hydrogel in osteogenic medium.  Mar-
ginal part of the image represents the dense layerof differentiated 
cells (osteoblasts). Cells were stained with hematoxylin and eosin 
(HE) dye, blue part representing the core, and the dark red part 
representing the cytoplasm of cells. Center of the bone graft repre-
sents a dense connective tissue consisting of matrix proteins.
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of tissues. Tissues may be restored with differentiated cells 
of the type normally found in the target tissue, or with 
progenitor cells, including stem cells that can differentiate 
into the mature cells of the tissue. Several cell types and 
tissues have been proposed as starting material; adult stem 
cells, embryonic stem cells, induced pluripotent stem 
cells, but some cell choices are more adaptable to cellular 
therapy in patients. Today, the general opinion is that 
mesenchymal stem cells from adult tissues are the most 
suitable for bone tissue engineering. ESCs and iPSCs al-
low the study of human development and tissue forma-
tion under diverse experimental conditions and represent 
an excellent base for understanding human diseases and 
developing innovative therapeutic solutions. 
The near future of bone healing and regeneration is 
closely related to advances in tissue engineering. Perhaps 
therapy using scaffolds, healing factors and stem cells to-
gether would be able to solve the current limitations in 
managing bone injuries. Bone constructs elaborated with 
tissue engineering principles are a promising substitute for 
autologous bone graft and have long been considered the 
golden standard for repair of large bone defects. Although 
application of MSCs as cellular material facilitates the 
construct fabrication, there is still some issues with MSC 
preparation mainly due to expansion in culture that can 
affect their genome and phenotype. However, more work 
needs to be done to fully determine the clinical potential, 
efficacy, and safety of stem cell-based treatments.
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